Modified fluorinated nucleoside analogues
First Claim
Patent Images
1. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
7 Assignments
0 Petitions
Accused Products
Abstract
The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.
-
Citations
129 Claims
-
1. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L ) of the formula;
- View Dependent Claims (2, 3)
- R)-2′
-
4. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L ) of the formula;
- View Dependent Claims (5)
- R)-2′
-
6. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L ) or its pharmaceutically acceptable salt or prodrug thereof of the structure;
- View Dependent Claims (7, 8)
- R)-2′
-
9. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L ) of the formula;
- R)-2′
-
10. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L ) of the formula
- R)-2′
-
11. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
12. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
13. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
14. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
15. A (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
16. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (17, 18)
- R)-2′
-
19. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (20)
- R)-2′
-
21. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) or its pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier, of the structure;
- View Dependent Claims (22, 23)
- R)-2′
-
24. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
25. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
26. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier of the formula;
- R)-2′
-
27. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L), or its pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier, of the formula;
- R)-2′
-
28. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier, of the formula;
- R)-2′
-
29. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof in a pharmaceutically acceptable carrier of the formula;
- R)-2′
-
30. A pharmaceutical composition comprising a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier, of the structure;
- R)-2′
-
31. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (32, 33)
- R)-2′
-
34. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (35)
- R)-2′
-
36. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) or its pharmaceutically acceptable salt or prodrug thereof of the structure;
- View Dependent Claims (37, 38)
- R)-2′
-
39. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
40. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
41. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
42. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
43. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
44. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2R)-2′
- -deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- -deoxy-2′
-
45. A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
46. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (E-D or β
-L) of the formula;
- View Dependent Claims (47, 48)
- R)-2′
-
49. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (50)
- R)-2′
-
51. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) or its pharmaceutically acceptable salt or prodrug thereof of the structure;
- View Dependent Claims (52, 53)
- R)-2′
-
54. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
55. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2R)-2′
- -deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- -deoxy-2′
-
56. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
57. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
58. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
59. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
60. A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
61. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (62, 63)
- R)-2′
-
64. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (65)
- R)-2′
-
66. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) or its pharmaceutically acceptable salt or prodrug thereof of the structure;
- View Dependent Claims (67, 68)
- R)-2′
-
69. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
70. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
71. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
72. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
73. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
74. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
75. A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
76. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (77, 78)
- R)-2′
-
79. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) of the formula;
- View Dependent Claims (80)
- R)-2′
-
81. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) or its pharmaceutically acceptable salt or prodrug thereof of the structure;
- View Dependent Claims (82, 83)
- R)-2′
-
84. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
85. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
86. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
87. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
88. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
89. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
90. A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
91. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- View Dependent Claims (92, 93)
- R)-2′
-
94. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) of the formula;
- View Dependent Claims (95)
- R)-2′
-
96. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) or its pharmaceutically acceptable salt or prodrug thereof of the structure;
- View Dependent Claims (97, 98)
- R)-2′
-
99. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
100. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) of the formula;
- R)-2′
-
101. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
102. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
103. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
104. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
105. A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula;
- R)-2′
-
106. The method of 31, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMDPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
107. The method of 41, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
108. The method of 43, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
109. The method of 45, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
110. The method of 46, wherein the antivirally effective amount of (2′
- R)-2′
deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
111. The method of 56, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
112. The method of 58, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
113. The method of 60, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
114. The method of 61, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
115. The method of 71, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
116. The method of 73, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
117. The method of 75, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
118. The method of 76, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
119. The method of 86, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
120. The method of 88, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
121. The method of 90, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
122. The method of 91, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
123. The method of 101, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
124. The method of 103, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
125. The method of 105, wherein the antivirally effective amount of (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of;
interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega;
an interleukin, including interleukin 10 and interleukin 12;
ribavirin;
interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin;
levovirin;
a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor;
a helicase inhibitor;
a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor;
gliotoxin;
an IRES inhibitor; and
antisense oligonucleotide;
a thiazolidine derivative;
a benzanilide, a ribozyme;
another nucleoside, nucleoside prodrug or nucleoside derivative;
a 1-amino-alkylcyclohexane;
an antioxidant including vitamin E;
squalene;
amantadine;
a bile acid;
N-(phosphonoacetyl)-L-aspartic acid;
a benzenedicarboxamide;
polyadenylic acid;
a benzimidazoles;
thymosin;
a beta tubulin inhibitor;
a prophylactic vaccine;
an immune modulator, an IMPDH inhibitor;
silybin-phosphatidylcholine phytosome; and
mycophenolate.
- R)-2′
-
126. A method of synthesizing a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) comprising glycosylation of a nucleobase with an intermediate structure;
- R)-2′
-
127. A method of synthesizing a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L) comprising selective deprotection of either Pg in an intermediate of the structure;
- R)-2′
-
128. An intermediate in the synthesis of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L), wherein the intermediate is of the structure;
- R)-2′
-
129. An intermediate in the synthesis of a (2′
- R)-2′
-deoxy-2′
-fluoro-2′
-C-methyl nucleoside (β
-D or β
-L), wherein the intermediate is of the structure;
- R)-2′
Specification